Key Highlights

● Revenue rose even as membership fell

● Net profit replaced a heavy loss

● Full-year outlook raised well above the prior range

● New CEO and open payer talks shape the next stage

agilon health, inc. (NYSE:AGL), a value-based primary care platform in the US healthcare sector, reported third-quarter results that landed well above the forecast management had offered only a few months earlier. Revenue rose from the prior-year period, a heavy net loss turned into a net profit, and the Westerville, Ohio, company raised its full-year guidance for revenue, membership and adjusted EBITDA. The release, furnished to the SEC, showed improvement across almost every profitability measure, even as the membership count declined.

The gap between forecast and outcome is the most striking feature of the report. On the August call covering the second quarter, Chief Financial Officer Jeff Schwaneke guided to "break even adjusted EBITDA" for the third quarter. The figure actually reported was a clearly positive one, compared with a substantial adjusted EBITDA loss in the same quarter of the prior year. Revenue also finished above the level he had described, and the Margin the company earned on its medical book came in well above his forecast too.

Chief Executive Officer Tim O'Rourke said results "exceeded" expectations, crediting disciplined execution and operational progress. He tied that performance to the company's proximity to physicians and patients, which he said pairs trusted relationships with actionable insights.

How Revenue Rose While Membership Fell

On the surface, higher revenue from fewer members looks contradictory, and the release addresses this directly. Management attributed the increase to higher-than-expected burden of illness performance, payer contracting and improved pricing, which together more than offset the effect of lower membership. Burden of illness refers to the recorded health complexity of the patients in a plan, which feeds into the payments that flow through Medicare Advantage arrangements.

Membership moved in the opposite direction. Medicare Advantage members at the end of the period were down from a year earlier, accountable care organization members were modestly lower, and the total number of people on the platform declined as well. The company said the changes reflect a profitability-focused contracting approach, previously disclosed market exits and measured growth. In other words, the shrinkage was described as a deliberate outcome and not simply as attrition.

The company describes itself as a provider of technology, people, capital, process and access to a peer network of primary care physicians. Its purpose is to support physician groups and health systems as they move to a value-based Total Care Model for senior patients, in which economic results depend on managing the full cost of care rather than on the Volume of visits. That design explains why the company's fortunes are so sensitive to the relationship between what payers remit and what care ultimately costs.

The Medical Margin Is Where the Turnaround Lives

The clearest measure of that relationship is the medical services expense ratio, which compares the cost of care with the revenue attached to it. In the third quarter, that ratio improved dramatically from the prior-year level, when expenses had exceeded medical services revenue outright. The company noted that the latest period included favorable claims development from the first half of the year, a point worth keeping in view when judging how much of the improvement is likely to recur.

Medical services expense itself fell from the year-earlier quarter even as medical services revenue climbed. Other medical expenses increased substantially, and general and administrative costs moved higher, partly on stock-based compensation. Depreciation was slightly lower. Even so, the arithmetic left Operating Income firmly positive, compared with a large operating loss a year before.

Below the operating line, the picture was more mixed. Equity method results swung from income to a small loss, other income rose, interest expense was little changed and the company recorded a tax expense in place of a small prior-year benefit. Net Income and Diluted Earnings per Share both turned positive from sizable losses. Year-to-date results told the same story: revenue was modestly higher, and net income and adjusted EBITDA each moved from a loss to a profit, while Operating Cash Flow turned positive after a significant outflow in the same stretch of the prior year.

Reading the Raised Outlook

The revised guidance widened the distance from where the year began. The adjusted EBITDA range moved far above the prior range, with even the new range's low end sitting above the old range's high end. The revenue range also rose, and its low end now sits just above the high end of the previous span. The expected medical services expense ratio improved, and every membership measure was lifted, including year-end Medicare Advantage and accountable care organization members. Geography entry costs were left unchanged.

The outlook also offers an implied message about the final quarter. Comparing the year-to-date adjusted EBITDA with the new full-year range shows that the remaining quarter is expected to produce a loss, since the year-to-date total already exceeds the top of the range. That is consistent with what Schwaneke said in August, when he told analysts that the highest-earning quarters come in the first half and the lowest in the second half. Readers comparing one quarter with the next would need to account for this seasonal shape.

The company did not offer a net income outlook or a reconciliation of adjusted EBITDA to net income for the year, citing uncertainty around items such as stock-based compensation. It expects its accountable care organization entities, which are not consolidated in revenue, to contribute to full-year adjusted EBITDA, and those entities added to the third-quarter total, though by less than in the prior-year quarter.

Contracts, Part D and the Price of Holding Firm

Much of the financial recovery traces to a contracting reset that management has described in detail over the past year. At a Jefferies (NYSE:JEF) healthcare conference in September, Schwaneke characterized the shift as "pivoting the company towards profitability from growth," following a period in which medical cost trends outpaced reimbursement. Levers he listed included disciplined contracting, quality incentives, carve-outs of Part D risk, burden of illness programs, an Operating Expense reduction, and data and artificial intelligence tools.

He said most of the contract book was touched a year ago, and that roughly half of it is open during the current cycle, including a portion that was left untouched last time. The focus, he said, is on securing a defined share of the premium dollar. A meaningful group of members left risk arrangements when terms could not be agreed. He told the conference audience that the company had held the line on economic terms and intended to keep doing so.

Prescription drug exposure has been a particular target. Part D full-risk exposure has been reduced sharply compared with the prior year, and on the second-quarter call Schwaneke said the company's remaining exposure covered a small minority of the book, with an aim of reducing it further. In September, he added that one payer had agreed to a Carve-Out for next year and that discussions with others were continuing.

A Federal Rate Backdrop That Turned Less Harsh

The company's progress is occurring against a shifting federal payment environment. In April, the Centers for Medicare and Medicaid Services finalized its payment policies for the coming plan year, projecting an increase in payments to Medicare Advantage plans well above what its earlier advance notice had suggested. The agency also decided against finalizing a new risk adjustment model, opting to keep the existing one and saying this would give the market more time to adjust.

Market commentary noted at the time that the final rate came in higher than analysts had anticipated and that major insurers' shares rose after hours following the rule. The publication also noted that insurers had been trimming membership to prioritize profitability and that margin recovery depended on factors such as medical utilization and quality ratings. It also reported that groups including America's Physician Groups said the increase still fell short of actual cost pressures.

CMS did finalize one change that bears directly on the risk-related revenue that value-based groups depend on: diagnoses from chart reviews not linked to a specific encounter will be excluded, with an exception for beneficiaries switching between plans. Schwaneke said at the September conference that he expected the risk adjustment lift next year to fall within a range running from flat to moderately positive, and that it would be "a net positive, so more than offset normalization." Those remarks predate the latest report and represent management's expectation, not an established outcome.

Payers Are Pulling Back, and That Cuts Both Ways

Insurers' own retrenchment forms another layer of context. CMS has projected a slight decrease in the national count of Medicare Advantage plans for next year, and In September, every major insurer cut individual plans, citing analysis by Stephens. The publication reported that insurers projected lower Medicare Advantage enrollment next year and that benefit packages were tightening across much of the market.

For a physician enablement platform, that environment presents both pressure and opportunity. Payers focused on their own margins may negotiate hard, and fewer plans can mean less membership to manage. At the same time, the higher year-end membership range in agilon health's new guidance suggests management saw a somewhat better outcome than it had previously expected for the current year. The release does not, however, offer membership guidance for next year, and the annual enrollment period that CMS scheduled from mid-October into early December, which will shape it, was still in progress when the results were released.

Clinical Programs and the Data Layer

Alongside contracts, management has pointed to clinical programs as a source of durable improvement. On the second-quarter call, O'Rourke said the congestive heart failure program had been deployed across most of the company's markets, and he cited a large fall in the share of first heart failure diagnoses made in an inpatient setting. Earlier diagnosis in the community is intended to improve care while avoiding costly hospital stays, which is the central logic of a value-based arrangement.

O'Rourke identified dementia and chronic obstructive pulmonary disease pathways as next areas of focus for the rest of the year. He also framed artificial intelligence as a support rather than a substitute for clinicians, calling it "a force multiplier for primary care." Schwaneke said a large majority of the company's payers were included in its data pipeline, with onboarding expected to slow as smaller payers are added.

Cash, Settlement Timing and the Balance Sheet

The Balance Sheet shows both the strength of the recovery and its timing lag. Cash, restricted cash and marketable securities rose from the level reported at the end of June, while Debt remained small relative to that liquidity. Unconsolidated accountable care organization entities also held cash of their own. Stockholders' equity increased from the end of the prior year, and receivables rose substantially over the same stretch, as did Accounts Payable and accrued expenses.

The rise in receivables is relevant because profits earned in a value-based model do not arrive immediately. Schwaneke explained in September that payer margin settlements occur in the third quarter of the following year, which means earnings booked this year are expected to convert into cash next year. He said he expected positive cash flow next year. That timing helps explain how the company can post a strong income statement while its cash generation trails behind.

A New Chief Executive and the Road Into Next Year

The quarter was recorded under a relatively new leader. The release's forward-looking disclosure lists a chief executive transition among its risk considerations, along with new geography and payer development, Medicare Advantage contracting and other factors outlined in the annual report. The company has said new market expansion is not a near-term priority: O'Rourke said the company would stay "measured and disciplined" on new markets, while Schwaneke cited a long implementation lead time for new full-risk partners.

The nearer path to growth, according to Schwaneke, involves converting existing care coordination members into full-risk arrangements, potentially recovering members who left if acceptable terms are reached, and expanding the accountable care organization business. That last piece is itself in flux. O'Rourke said on the August call that the company was evaluating the path forward for existing and new accountable care organization partners, and Schwaneke said in September that applications had been filed for both the ACO LEAD model and the Medicare Shared Savings Program, with the final choice still being evaluated.

They include how much of the medical cost improvement reflects favorable development from earlier periods, what economic terms the current round of contract talks produces, how membership settles once open enrollment closes, and how risk adjustment behaves next year under the new chart review limits. The company's raised outlook describes a far stronger year than it projected only months ago, while its own disclosures make clear that seasonal patterns, settlement timing and payer negotiations will continue to determine how those results translate into the following year.